The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma
- 22 July 2017
- journal article
- laboratory investigation
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 135 (1) , 47-56
Abstract
Neurofibromatosis type 2 (NF2), a neurogenetic condition manifest by peripheral nerve sheath tumors (PNST) throughout the neuroaxis for which there are no approved therapies. In vitro and in vivo studies presented here examine agents targeting signaling pathways, angiogenesis, and DNA repair mechanisms. In vitro dose response assays demonstrated potent activity of lapatinib and nilotinib against the mouse schwannoma SC4 (Nf2 −/−) cell line. We then examined the efficacy of everolimus, nilotinib, lapatinib, bevacizumab and radiation (RT) as mono- and combination therapies in flank and sciatic nerve in vivo NF2-PNST models. Data were analyzed using generalized linear models, two sample T-tests and paired T-tests, and linear regression models. SC4(Nf2 −/−) cells implanted in the flank or sciatic nerve showed similar rates of growth (p = 0.9748). Lapatinib, nilotinib and RT significantly reduced tumor growth rate versus controls in the in vivo flank model (p = 0.0025, 0.0062, and 0.009, respectively) whereas bevacizumab and everolimus did not. The best performers were tested in the in vivo sciatic nerve model of NF2 associated PNST, where chemoradiation outperformed nilotinib or lapatinib as single agents (nilotinib vs. nilotinib + RT, p = 0.0001; lapatinib versus lapatinib + RT, p < 0.0001) with no observed toxicity. There was no re-growth of tumors even 14 days after treatment was stopped. The combination of either lapatinib or nilotinib with RT resulted in greater delays in tumor growth rate than any modality alone. This data suggest that concurrent low dose RT and targeted therapy may have a role in addressing progressive PNST in patients with NF2.Keywords
This publication has 48 references indexed in Scilit:
- Prolonged Clinical Benefit of Everolimus Therapy in the Management of High-Grade Pancreatic Neuroendocrine CarcinomaCase Reports in Oncology, 2013
- Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problemsActa Neuropathologica, 2012
- Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2American Journal of Medical Genetics Part A, 2011
- Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinibCancer Chemotherapy and Pharmacology, 2011
- mTOR Inhibitors in Advanced Renal Cell CarcinomaHematology/Oncology Clinics of North America, 2011
- ErbB Expression, Activation, and Inhibition With Lapatinib and Tyrphostin (AG825) in Human Vestibular SchwannomasOtology & Neurotology, 2011
- Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2Neuro-Oncology, 2011
- ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannomaNeuro-Oncology, 2010
- FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivoBritish Journal of Cancer, 2009
- Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumorsMolecular Cancer Therapeutics, 2008